{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-062270","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.346841+00:00","generated_at":"2026-06-01T22:22:08.479001+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Theriva Biologics receives conversion notice for 135,431 Series C Preferred shares into ~888K common shares","bullets":["Holder converted 135,431 Series C Preferred shares into 888,072 common shares at $1.22 per share.","Conversion increases outstanding common shares by approximately 888,000, diluting existing shareholders.","Notice received May 13, 2024; conversion effective upon notice."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-062270","json":"https://secwatch.observer/filing/0001104659-24-062270.json","markdown":"https://secwatch.observer/filing/0001104659-24-062270.md","text":"https://secwatch.observer/filing/0001104659-24-062270.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465924062270/0001104659-24-062270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465924062270/tm2414630d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:22:08.479001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}